drugset / Trial / NCT05922501
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Phase 2
Recruiting
50 enrolled
Massachusetts General Hospital
GlaxoSmithKline · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.
Timeline
- Start
- 2024-05-31
- Primary completion
- 2028-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | — | Intravenous |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Isatuximab | Monoclonal antibody | — | Intravenous |
| Subject | Pomalidomide | Other / unclassified | — | Oral |